Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dermata Therapeutics Inc. (DRMA:NASDAQ), powered by AI.
Dermata Therapeutics Inc. is currently trading at $1.19. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Dermata Therapeutics Inc. on Alpha Lenz.
View Dermata Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Dermata Therapeutics Inc.'s ROE is -194.2%. Explore profitability and growth together.”
Ask for details →Dermata Therapeutics Inc. is a clinical-stage biotechnology company committed to developing and commercializing pharmaceutical solutions for dermatological conditions. The company's core focus is on creating innovative therapies to address unmet medical needs within dermatology, with a particular emphasis on skin diseases like acne, rosacea, and psoriasis. Dermata's proprietary technology aims to improve the efficacy and safety profiles of topical treatments, which are critical for patient compliance and therapeutic success. Through its research and development efforts, Dermata impacts the healthcare sector by seeking to enhance the quality of life for individuals with dermatological conditions. Its contribution is significant in pinpointing novel drug candidates that might advance clinical standards and offer alternative treatment modalities. Dermata Therapeutics Inc. plays an important role in the biopharmaceutical industry by advancing science-driven solutions that address complex challenges within the field of dermatology.
“Dermata Therapeutics Inc.'s ROE is -194.2%. Explore profitability and growth together.”
Ask for details →Dermata Therapeutics Inc. (ticker: DRMA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 8 employees.
The current price is $1.19 with a P/E ratio of -x and P/B of -x.
ROE is -194.20%.